Oracle Health Sciences Earns Frost & Sullivan’s Enabling Technology Leadership Award for its eClinical Platform, Clinical One

Clinical One Randomization and Supplies Management Cloud Service Enables Unparalleled Transparency and Efficiency Throughout the Clinical Development Life Cycle

SANTA CLARA, California, June 21, 2018 /PRNewswire/ — Based on its recent analysis of the North American clinical trial IT solutions market, Frost & Sullivan recognizes Oracle Health Sciences with the 2018 North American Enabling Technology Leadership Award for its new eClinical platform, Clinical One™ and the first module released on the platform, Clinical One Randomization and Supplies Management Cloud Service.

Frost & Sullivan recognizes Oracle Health Sciences with the 2018 North American Enabling Technology Leadership Award for its new eClinical platform, Clinical One™.
Frost & Sullivan recognizes Oracle Health Sciences with the 2018 North American Enabling Technology Leadership Award for its new eClinical platform, Clinical One™.

Click here to read the full report – https://go.oracle.com/frostandsullivanaward  

“The Clinical One platform provides Oracle’s life sciences customers with a modern, collaborative cloud environment that eliminates massive redundancies, thus creating process efficiencies and seamless sharing of information across functions and all stages of drug development,” said Kamaljit Behera, industry analyst, Frost & Sullivan. “The platform empowers the clinical trial industry to reengineer its operations with a digital continuity theme, thereby driving unparalleled transparency and efficiency throughout the clinical development life cycle.”

Clinical One has been built from the ground up to support all functions in the clinical development life cycle, unlike other eClinical point solutions on the market today, which only support one function or process.  The platform eliminates redundancies and creates process efficiencies by leveraging Oracle’s cloud services, such as platform as a service (PaaS) and infrastructure as a service (IaaS), and introduces foundational features and common functions that are shared across all modules, requiring data to be entered only once. The resulting cost and time savings help pharmaceutical companies, biotechs and CROs bring new therapies to market faster to patients waiting in need.

Oracle Health Sciences Clinical One was built with the latest microservice architecture that offers scalability for continuously developing and deploying large, complex applications. It also provides built-in interoperability for seamless integration with existing IT systems across client operations and incorporation of mid-study changes or amendments. Furthermore, it runs on the company’s RESTful Web services and allows users to modify or view resources on the server without performing any server-side operations. On the pricing front, the cloud-based, multi-tenant system and the scalable microservices architecture make it easy to provide the Clinical One platform at an extremely competitive SaaS-based flexible pricing model, especially when compared to traditional technology licensing models.

“We are honored to be recognized for reimagining the way technology supports clinical research with Clinical One,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “We believe in universal access to clinical trial data that is entered once, secured in the cloud and shared across all study team members. This evolution in eClinical technology was long overdue, and we were in the best position to make it happen.  Starting with the RTSM module now, and the other modules that will follow, our customers are excited about the cost and time savings Clinical One promises to deliver.”

In 2017, Oracle Health Sciences successfully launched the Randomization and Supplies Management Cloud Service as the first capability on Clinical One. The RTSM module has a built-in, self-guided workflow for study design and randomization to empower clinical teams to design, validate, and deploy a study in days instead of weeks or months. In addition to managing patient randomization and trial supplies, the RTSM module leverages Clinical One’s foundational capabilities to monitor recruitment with real-time status reports, manage emergency treatment code breaking, and perform calculations to ensure dosing accuracy.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current systems or workflows, but also enables the development of new digital solutions and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Oracle Health Sciences
Oracle Health Sciences breaks down barriers and opens new pathways to unify people and processes to bring new drugs to market faster. As the number one vendor in Life Sciences (IDC, 2017), the number one provider of eClinical solutions (Everest Group, 2017) and powered by the number one data management technology in the world (Gartner, 2018), Oracle Health Sciences technology is trusted by 29 of the top 30 pharma, 10 of the top 10 biotech and 10 of the top 10 CROs for clinical trial and safety management around the globe.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

Related Post